← Back to Briefing
Tempus AI Acquires Personalis for $1.7 Billion to Enhance AI-Driven Oncology and Genomic Testing
Importance: 93/1002 Sources
Why It Matters
This strategic acquisition represents a major consolidation in the precision medicine and AI-driven healthcare sector, poised to accelerate the development and application of advanced genomic insights for cancer diagnosis and personalized treatment.
Key Intelligence
- ■Tempus AI has entered into a definitive agreement to acquire Personalis, a cancer-focused genomic testing company.
- ■The all-stock transaction is valued at approximately $1.7 billion.
- ■The acquisition aims to significantly expand Tempus AI's capabilities in AI-driven oncology and genomic testing.
- ■Personalis shareholders will receive 0.0415 shares of Tempus Class A common stock for each share of Personalis common stock.
Source Coverage
Google News - AI & Bloomberg
7/20/2026Tempus to Buy Cancer-Tech Firm Personalis for $1.7 Billion - Bloomberg.com
Google News - AI
7/20/2026